Irushi Abeysekera

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

Megan Stringer, Irushi Abeysekera, Jared Thomas et al. · Physiology & Behavior · 2017 · 57 citations · Full text

Down Syndrome, Ts65dn Model, Physiology +4

Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function

Safa Mohamad, Linlin Xu, Joydeep Ghosh et al. · Blood Advances · 2017 · 55 citations · Full text

Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic<i>Dyrk1a</i>

J Blazek, Irushi Abeysekera, Jiliang Li et al. · Human Molecular Genetics · 2015 · 51 citations · Full text

Down Syndrome, Bone Disease, Peripheral Skeletal Anomalies +14

Skeletal adaptations in young male mice after 4 weeks aboard the International Space Station

Kevin A. Maupin, Paul Childress, Alexander Brinker et al. · npj Microgravity · 2019 · 43 citations · Full text

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model

Megan Stringer, Irushi Abeysekera, Karl J. Dria et al. · Pharmacology Biochemistry and Behavior · 2015 · 42 citations

Down Syndrome, Neuropsychological Functioning, Neuropsychology +10